---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-167929"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:29:04.991045+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma grants 356,900 options to CEO and 153,000 to Exec Director at $0.23/share

## Summary
- CEO Dr. Jerel Banks granted nonqualified stock options for 356,900 shares at $0.23 per share.
- Executive Director Megan Boston granted nonqualified stock options for 153,000 shares at $0.23 per share.
- Options vest in three equal annual installments, subject to continued service through each vesting date.
- Unvested options fully accelerate upon a Change in Control as defined in the 2020 Equity Plan.

## SEC filing metadata
- accession: 0001193125-23-167929
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523167929/0001193125-23-167929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523167929/d505671d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-167929
- JSON: https://secwatch.observer/filing/0001193125-23-167929.json
- Plain text: https://secwatch.observer/filing/0001193125-23-167929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.